The case for & against
Bull & Bear analysis
Bearish
Theriva Biologics, Inc. (NASDAQ: THRV) specializes in developing innovative oncolytic virus therapies targeting hard-to-treat cancers such as pancreatic ductal adenocarcinoma (PDAC) and retinoblastoma. Leveraging proprietary technologies like VCN01, the company is positioned at the forefront of cancer treatment innovation and biotechnology, aiming to combat significant unmet medical needs while navigating the complexities of regulatory frameworks to bring their therapies to market.
Bull says
- ↑VCN01 showed >21-month mean survival in early PDAC trials, indicating multi-modal tumor-killing potential.
- ↑Cash and equivalents of $23.2M extend runway into Q1 2025, funding VARAGE Phase II trial.
- ↑FDA meetings planned for pediatric retinoblastoma may enable expedited approval pathways.
- ↑Pipeline expansion and ESMO data presentations could drive positive readthrough for VCN01.
- ↑Enrollment in VARAGE Phase II expected to complete H1 2024, a key catalyst.
- ↑Factor analysis shows high growth theme, strong liquidity, and positive quality score.
Bear says
- ↓R&D expenses rose to $14.3M in 2023, up 22% YoY, pressuring cash.
- ↓Cash declined to $23.2M from $41.8M year-over-year, raising refinancing risk.
- ↓Lack of specific FDA guidance on retinoblastoma may extend approval timelines.
- ↓VARAGE Phase II trial faces enrollment delays and adverse event risks.
- ↓Market adoption uncertain amid competition from established oncology therapies.
- ↓Factor analysis flags negative earnings yield, weak profitability, and revision concerns.
Investment themes with TOVX
Biotech↑ +0.07%
Genetic and drug innovations driving medical breakthroughs
ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q4 2022 · Mgmt. Guidance
Updated 07-04-2026neutral
Transcript signals
Bull points
- we expect to present this data probably at ESMO in 2023, that it's going to be in the last part of September of 2023. It's an international meeting. It's going to be held in Madrid, in Spain. So we expect to do a release at that point of all the survivability data that we have at that point.
- During the full year of 2022 and the first few months of 2023, we continue to make significant progress across our oncology folks portfolio.
- With these studies, we look forward to building on the growing data that underscore VCN01's differentiated mechanism of action, biological activity, and synergistic clinical benefit observed in combination with standard-of-care chemotherapy.
Bear points
- Progress to the second cohort was permitted by an independent safety monitoring committee after a detailed review of safety and pharmacokinetic data from the first antibiotic cohort administering Maripenem.
- General administrative expenses increased to $9.9 million for the year end December 31, 2022 from $6.5 million for the year ended December 31, 2021.
- This increase of approximately 50.8% is primarily comprised of increased expense related to the fair value of contingent consideration, higher insurance costs, additional salary and benefits related to new headcount, public relations expense, and VCNO administrative expenses not included in the prior year.
Read full transcript analysis ›